In a Dublin laboratory, tiny LEGO-like particles are offering a new lifeline against the deadliest childhood cancer. At RCSI University of Medicine and Health Sciences, Dr. Olga Piskareva and her team have developed an mRNA vaccine that slashes tumor size by 70% in preclinical models of neuroblastoma—a disease responsible for 15% of all childhood cancer deaths. This breakthrough, published in Molecular Therapy Oncology, marks the first evidence that an mRNA vaccine can effectively target neuroblastoma, a cancer that strikes five to ten children in Ireland each year and resists treatment in 80% of cases.
Neuroblastoma is especially cruel. Often diagnosed in toddlers, it arises from immature nerve cells and can spread rapidly before symptoms appear. When it returns after initial therapy, it typically becomes resistant to existing treatments, leaving families with few options. But Piskareva’s vaccine works differently: it uses peptide nanoparticles—tiny self-assembling carriers—to deliver mRNA instructions that train the immune system to recognize Glypican 2 (GPC2), a protein abundant on neuroblastoma cells. In mouse models, the vaccine delayed tumor development by 10 to 11 days, a significant window in early cancer intervention, and triggered a robust immune response that shrank tumors by more than two-thirds.
The innovation lies not just in the target, but in the delivery. These peptide nanoparticles act like precision-guided messengers, ensuring the mRNA reaches the right immune cells without degrading. Because GPC2 is also present in other cancers, including certain brain and lung tumors, this platform could be adapted far beyond neuroblastoma. That versatility is what makes the approach a potential game-changer in cancer immunotherapy. As Piskareva explains, “The mRNA vaccine technology is like LEGO bricks. By combining different bricks, we can tailor the vaccine to the individual's needs with high precision.”
While still in preclinical stages, the results are compelling enough to ignite hope. For families facing a diagnosis with few options, this vaccine represents more than a scientific advance—it’s a promise of longer, healthier lives. The next steps involve refining the vaccine for human trials and exploring its use in combination with existing therapies. With mRNA technology already proven in infectious disease, its leap into pediatric oncology could redefine what’s possible. The road ahead is long, but as Piskareva notes, the first milestone has been reached. And in the fight against childhood cancer, every milestone counts.